Search Results

Ascendis Pharma A/S announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

electroCore, Inc. announced it has entered into an agreement with Teijin Limited, a global conglomerate based in Japan offering advanced solutions in the fields including healthcare, material and information technology, to license certain exclusive rights to its non-invasive vagus nerve stimulation technology for commercialization in Japan for a range of primary headache disorders.

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.

VolitionRx Limited, a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited, a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions.

Bionomics Limited announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares and accompanying warrants in a three-tranche private placement.